Clinical Trial

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

Dimensions: NCT02576574

Investigators

Affiliations

Organisations

Sponsors/collaborators

Abstract

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Methods

Condition: First Line Non-Small Cell Lung Cancer

Intervention: Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once a week for 12 weeks and then once every 2 weeks until disease progression or unacceptable toxicities.

Recruitment information

Gender: All

Trial period

2015-2025

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry